Today’s Boston Business Journal contains a fascinating article about a local company, Generate Biomedicines, now utilizing machine learning software to create “purpose-built proteins capable of performing any desired function” through protein sequencing.  Although this stated result may prove over-broad, the goal is to invent proteins addressing a wide spectrum of diseases.  They now have a Phase 1 running on a monoclonal COVID-19 antibody.

That kind of ambition (and performance) has attracted a partnership with Amgen and a just-concluded Series C raise of $273M.  AI-based medical initiatives not surprisingly can attract significant financial support, even at a relatively early stage.